MHRA strengthens botulinum toxin safety warnings over iatrogenic botulism risk

The Medicines and Healthcare products Regulatory Agency is strengthening safety warnings for all UK-authorized botulinum toxin type A products due to the risk of iatrogenic botulism, meaning clinics must update their consent processes and patient post-care instructions. Although distant toxin spread has been noted in UK product information since 2007, updated patient leaflets starting July 15, 2026, will explicitly name iatrogenic botulism and direct patients to seek emergency medical attention. These symptoms, which can appear up to four weeks after treatment, include difficulty swallowing, slurred speech, breathing difficulties, and severe eyelid drooping.

The warning covers major brands, including Botox and Azzalure 125 units, and highlights that risk increases with high doses, off-label use, or unapproved injection sites. To maintain compliance and patient safety, injectors should reinforce the maximum twelve-week treatment interval and explicitly advise patients to call 999 if they experience respiratory or swallowing issues. You will need to revise your consent forms to document that these specific risks and the four-week symptom window were discussed prior to injection.

Source: Faces Consent, https://facesconsent.com/mhras-new-botulism-warning-what-to-change-now/